daraxonrasib

Phase 3

Revolution Medicines, Inc. (RVMD)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Past

days

RVMDRegulatory$41.1B

Phase 3✓Positive

Regulatory Decision - daraxonrasib

daraxonrasib• NSCLC (Non-small Cell Lung Cancer)

Sep 30AI-detected

Source

Competitive Landscape

1 competitor in NSCLC (Non-small Cell Lung Cancer)

View Full Landscape

Drug Information

Target Indication

NSCLC (Non-small Cell Lung Cancer)

Clinical Trial

NCT06881784

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Rasonque

Treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RVMD

Revolution Medicines, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

pemetrexed + cisplatin/carboplatinPhase 3

NSCLC

Liposomal irinotecanPhase 3

Pancreatic Cancer

RMC-6236Phase 3

Colorectal Cancer

zoldonrasibPhase 3

Pancreatic Cancer

Leucovorin (Calcium Folinate)Phase 3

Pancreatic Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts